Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q3 EPS of ($0.86), $0.12 better than the analyst estimate of ($0.98). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $303.33 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.